Rigontec is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The Company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The Company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens.
|Wellington Partners, Sunstone Capital, High-Tech Gruenderfonds, NRW.BANK, Forbion Capital Partners, MP Healthcare Venture Management, Boehringer Ingelheim Venture Fund|
When was Rigontec founded?
Rigontec was founded in 2014.
Who are Rigontec key executives?
Rigontec's key executives are Christian Schetter, Anne Burger and Eugen Leo.
Who are Rigontec competitors?
Competitors of Rigontec include EBT Medical, AdaptHealth and Tactile Medical.
Where is Rigontec headquarters?
Rigontec headquarters is located at Innovations- und Gründerzentrum Biotechnologie (IZB) 19 Am Klopferspitz, Planegg.
Where are Rigontec offices?
Rigontec has offices in Planegg and Cambridge.
How many offices does Rigontec have?
Rigontec has 2 offices.
Receive alerts for 300+ data fields across thousands of companies